Glass Lewis Backs Pacira’s Board Nominees, Rejects DOMA’s Push for Sale
Event summary
- Glass Lewis recommends voting for Pacira’s three director nominees—Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans—and against DOMA Perpetual’s nominees ahead of the June 9, 2026, annual meeting.
- Glass Lewis cites Pacira’s 37% total stockholder return in 2025 and 23.8% cumulative return since launching the 5x30 strategy as evidence of effective leadership.
- DOMA Perpetual’s nominees are criticized for lacking the skills to execute a strategic review or sale, with Glass Lewis favoring Pacira’s current board and CEO Frank Lee’s long-term plan.
- Pacira’s 21 Orange Book-listed patents are highlighted as evidence of the board’s efforts to mitigate future risk and protect intellectual property.
The big picture
Pacira’s proxy fight underscores the tension between long-term strategic planning and activist investor demands for immediate value creation. Glass Lewis’ endorsement of Pacira’s board reflects broader industry trends where independent advisory firms increasingly weigh in on governance disputes, particularly in biotech, where pipeline progress and IP protection are critical. The outcome will signal whether Pacira’s 5x30 strategy can sustain momentum or if activist pressure accelerates a shift toward a sale.
What we're watching
- Governance Dynamics
- Whether Pacira’s board can maintain investor confidence amid DOMA Perpetual’s push for a strategic review or sale.
- Execution Risk
- The pace at which Pacira advances its pipeline products, PCRX-201 and PCRX-2002, to deliver topline accretion beyond 2030.
- Strategic Alignment
- How DOMA Perpetual’s influence may evolve post-annual meeting, given Glass Lewis’ endorsement of Pacira’s current strategy.
Related topics